| P2093 | author name string | Julia Wenger | |
| | David J A Goldsmith | |
| | Ravi Thadhani | |
| | Reza Hajhosseiny | |
| | Hector Tamez | |
| | Martin H de Borst | |
| P2860 | cites work | Bias in meta-analysis detected by a simple, graphical test | Q24685585 |
| | Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860606 |
| | Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 |
| | Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization | Q28283679 |
| | Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data | Q30656350 |
| | Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials | Q33413288 |
| | Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials | Q33836604 |
| | Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis | Q34120189 |
| | The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis | Q34122611 |
| | Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients | Q34123786 |
| | Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. | Q34254721 |
| | Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria | Q34504490 |
| | Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial | Q34625011 |
| | Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis | Q34660044 |
| | 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system | Q34793842 |
| | Changes in albuminuria predict mortality and morbidity in patients with vascular disease | Q35108899 |
| | Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease | Q35210184 |
| | Sodium intake, ACE inhibition, and progression to ESRD. | Q35720736 |
| | Associations of plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations with death and progression to maintenance dialysis in patients with advanced kidney disease | Q36227387 |
| | Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis | Q36336393 |
| | Estimating the financial cost of chronic kidney disease to the NHS in England | Q36358702 |
| | Paricalcitol does not improve glucose metabolism in patients with stage 3-4 chronic kidney disease | Q36431285 |
| | Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials | Q36567554 |
| | Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure | Q36902283 |
| | Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase | Q36924964 |
| | Chronic kidney disease, hypovitaminosis D, and mortality in the United States | Q37216938 |
| | Age and association of kidney measures with mortality and end-stage renal disease | Q37606084 |
| | Maxacalcitol ameliorates tubulointerstitial fibrosis in obstructed kidneys by recruiting PPM1A/VDR complex to pSmad3. | Q39289974 |
| | Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. | Q40509707 |
| | Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts | Q41931102 |
| | The GFR and GFR decline cannot be accurately estimated in type 2 diabetics | Q43588428 |
| | Retarding progression of chronic renal disease: the neglected issue of residual proteinuria | Q44445107 |
| | Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. | Q45930492 |
| | Renal protective effect of enalapril in diabetic nephropathy | Q46080832 |
| | Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 |
| | Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial | Q46497289 |
| | Individual titration for maximal blockade of the renin-angiotensin system in proteinuric patients: a feasible strategy? | Q46529781 |
| | Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials | Q46567269 |
| | Kidney function as a predictor of noncardiovascular mortality | Q46776022 |
| | Antiproteinuric effect of oral paricalcitol in chronic kidney disease | Q46826570 |
| | Short-term vitamin D receptor activation increases serum creatinine due to increased production with no effect on the glomerular filtration rate | Q48836184 |
| | 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. | Q51578714 |
| | Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. | Q53551859 |
| | Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial | Q57702534 |
| | Vitamin D levels and early mortality among incident hemodialysis patients | Q63681909 |
| | Renal function during calcitriol therapy in chronic renal failure | Q68724185 |
| | Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group | Q73632528 |
| | Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure | Q78197798 |
| | Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy | Q79326178 |
| | Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial | Q82147201 |
| | An open label, randomized controlled study of oral calcitriol for the treatment of proteinuria in patients with diabetic kidney disease | Q84199625 |
| P433 | issue | 11 | |
| P921 | main subject | vitamin | Q34956 |
| | systematic review | Q1504425 |
| | vitamin D | Q175621 |
| P304 | page(s) | 1863-1871 | |
| P577 | publication date | 2013-08-08 | |
| P1433 | published in | Journal of the American Society of Nephrology | Q17123893 |
| P1476 | title | Active vitamin D treatment for reduction of residual proteinuria: a systematic review | |
| P478 | volume | 24 | |